OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
Merck announces that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. • PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients. Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication […]
Read More...KEYTRUDA® (pembrolizumab) is indicated for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. SELECTED SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions • KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to […]
Read More...Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. • PD-L1 diagnostic testing is required prior to initiating treatment with […]
Read More...Join the Oklahoma Society of Clinical Oncology, Inc. for our fall meeting on November 6, 2021, ASCO Direct™, an officially licensed program of the American Society of Clinical Oncology®. This virtual meeting will break down the most clinically relevant abstracts from ASCO’s annual symposium, allowing attendees to engage with the latest strategies in oncology education. All exhibitors will have access to the full meeting application and will be able to view all the virtual sessions. Details of the virtual meeting are:
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at kmussonokc@gmail.com or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
